



MODIGENE TO PRESENT AT THE ROTH 2007 NEW YORK INVESTOR CONFERENCE

--Presentation to Be Webcast Live and Archived--

VIENNA, VA August 29, 2007 -- Modigene Inc. (OTCBB: MODG) today announced that senior management will present at the Roth 2007 New York Investor Conference on Thursday, September 6, 2007 at 3:00 pm EDT. The conference will be held at the Westin New York at Times Square in New York City.

Modigene CEO Abraham Havron and President Shai Novik will provide a company overview and review of corporate developments.

“As a relatively new public company, we look forward to this opportunity to inform additional investors about our innovative technology that has the potential to significantly extend the duration of virtually any therapeutic protein drug,” noted Dr. Havron. “We believe our product pipeline has great clinical and commercial promise as a result of our ability to increase the utility and convenience of a wide range of protein therapeutics currently used by millions of patients each year.”

The Modigene presentation will be webcast live and can be accessed by visiting www.wsw.com/webcast/roth13/modigene/. An archived version of the presentation webcast will also be available following the conclusion of the conference at the same address for approximately 90 days.

For more information about the Roth 2007 New York Investor Conference, visit www.roth.com/main/Page.aspx?PageID=7015.

ABOUT MODIGENE

Modigene Inc. (OTCBB:MODG) is a biopharmaceutical company applying its patented CTP technology to develop longer-acting, proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales. Modigene is currently developing long-acting versions of human growth hormone, erythropoietin, interferon beta, and GLP-1, which are in late preclinical development. For more information on Modigene, please visit www.modigeneinc.com.

***Safe Harbor Statement:** This press release contains forward-looking statements, including statements regarding the results of current studies and preclinical experiments and the effectiveness of Modigene's long-acting protein programs and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Modigene's business and prospects, including the risks that Modigene may not succeed in developing any commercial products based upon its long-acting protein technology, including any long-acting versions of human growth hormone, erythropoietin, interferon beta or GLP-1; that the long-acting products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The development of any products using the CTP platform technology could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and*

decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. In addition to the risk factors set forth above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Modigene's filings with the Securities and Exchange Commission.

MODIGENE CONTACT:

Shai Novik, President
Modigene Inc.
Tel: +1 866 644-7811
Email: shai@modigeneinc.com

MEDIA CONTACT:

Barbara Lindheim
GendeLLindheim BioCom Partners
+1 212 918-4650